Key Words: bradykinin Ⅲ barium Ⅲ forearm vasculature Ⅲ inward-rectifying potassium channels Ⅲ hyperpolarizing factor
P otassium ion (K ϩ ) channel activity is an important determinant of the membrane potential of vascular smooth muscle and, thus, of vascular tone. Inward-rectifying K ϩ channels (K IR ) in vascular smooth muscle differ from other vascular smooth muscle K ϩ channels (Ca 2ϩ -activated K ϩ channels, K Ca , voltage-dependent K ϩ channels, K V , and ATPsensitive K ϩ channels, K ATP ) in their unique current voltage properties and the consequent hyperpolarizing effect of increased external K ϩ . [1] [2] [3] K IR channels play a role in K ϩ -mediated dilation of rat coronary and cerebral arteries 4 and contribute to basal vasodilator tone in human forearm resistance vasculature. 5 K IR is more sensitive to Ba 2ϩ than other K ϩ channels, half-block being achieved at 2 mol L Ϫ1 at Ϫ60 mV in rat cerebral artery vascular smooth muscle, 6 Ϸ50-times more potent than on K ATP channels, Ͼ500-times as potent as on K V channels, and Ͼ5000-times as potent as on K Ca channels. 7 Brachial artery infusion of barium chloride in a dose that increases the local mean plasma concentration of Ba 2ϩ to 50 mol L Ϫ1 inhibits the vasodilator response to infused potassium chloride by 60Ϯ9%. 5 Electrogenic Na ϩ /K ϩ exchange also contributes to hyperpolarizing responses to K ϩ , and ouabain, an inhibitor of Na ϩ /K ϩ ATPase, inhibits forearm vasodilator responses to KCl by Ϸ33% in healthy men. 8 The combination of Ba 2ϩ plus ouabain in the same doses inhibits responses to K ϩ almost completely. 5 Coinfusion of barium chloride with ouabain thus provides a pharmacological tool to investigate whether increased extracellular K ϩ concentration contributes to vasodilator responses.
Activation of vascular smooth muscle K IR and Na ϩ /K ϩ ATPase by K ϩ released from endothelial cells causes endothelium-dependent hyperpolarization in rat hepatic arteries in vitro, 9 but the contribution, if any, of K ϩ to endotheliumdependent vasodilator agonists in vivo is less clearly established. Bradykinin is an endothelium-dependent vasodilator. In addition to releasing prostacyclin 10 and nitric oxide (NO) 11 from endothelial cells, it causes endothelium-dependent hyperpolarization of human coronary artery despite inhibition of prostaglandin (PG) and NO synthesis. 12 When infused via the brachial artery, it is a potent vasodilator in human forearm vasculature 13 by an action on B 2 receptors. 14 Bradykinininduced vasodilation in this vascular bed is not inhibited by aspirin 15 and is incompletely blocked by L-N G monomethylarginine (L-NMMA). 16 -19 Ouabain does not inhibit forearm responses to bradykinin in normotensive subjects but does significantly reduce such responses in patients with essential hypertension. 19 In the present investigation, we determined effects of Ba 2ϩ with or without ouabain on bradykinininduced vasodilation in healthy normotensive men without known risk factors for atheromatous vascular disease. Experiments were performed with or without inhibitors of NO and PG synthesis. Norepinephrine was used to control for nonspecific physiological antagonism caused by vasoconstriction caused by the inhibitors. Sensitivity of bradykinin to Ba 2ϩ plus ouabain was compared with 2 other endotheliumdependent agonists (acetylcholine and albuterol) that activate NO synthesis by distinct mechanisms in this vascular bed. 20 -22 ⌴ethods The St Thomas' Hospital Research Ethics Committee approved the studies and all subjects gave written informed consent. Healthy men aged 33Ϯ11 years (meanϮSD), nonsmokers using no medications, were invited to take part. Subjects were normotensive (blood pressure Ͻ130/80 mm Hg) and normocholesterolemic (total cholesterol Ͻ5.2 mmol L Ϫ1 ). Forearm studies were performed as described previously. 5 Blood flow was measured in both arms using venous occlusion plethysmography, and drugs dissolved in physiological saline were infused into the left brachial artery via a 27-gauge steel cannula. Each protocol was performed in a separate group of subjects to limit exposure to barium. Barium infusions (4 mol min Ϫ1 ) were given for 6 minutes. In each protocol, saline was first administered for 18 minutes to establish baseline flow. Vasodilators were infused for 3 minutes. Bradykinin (30 pmol min Ϫ1 ) was administered, followed by saline for 18 minutes, to re-establish baseline flow. Inhibitors were then administered for 3 minutes alone and for a final 3 minutes with bradykinin. 
Results
There were no adverse events or electrocardiographic changes. Arterial blood pressure and blood flow in the noninfused arm did not change significantly. Mean blood flows in the infused arm are summarized in Table 1 . Bradykinin increased blood flow similarly in each protocol, and each inhibitor reduced blood flow significantly. When coinfused with norepinephrine, the vasodilator effect of bradykinin was not significantly inhibited. Ba 2ϩ alone inhibited the vasodilator response to bradykinin by 26Ϯ8.3% (PϽ0.05), barium plus ouabain inhibited the response by 36Ϯ7.2% (PϽ0.05), and barium plus ouabain, indomethacin, and L-NMMA inhibited the response by 51Ϯ2.8% (PϽ0.01). When bradykinin was infused twice using the same protocol but in the absence of inhibitors, there was no evidence of desensitization: the response to the first versus second infusion was 8.6Ϯ1.7 versus 8.6Ϯ1.8 mL min Ϫ1 100 mL forearm Ϫ1 (nϭ6, PϭNS). Ba 2ϩ plus ouabain did not significantly reduce vasodilator responses to acetylcholine or to albuterol (Table 2) , which also shows the effect of these inhibitors on bradykinin for comparison.
Discussion
The main finding is that Ba 2ϩ (plasma concentration Ϸ50 mol L Ϫ1 ) 5 selectively inhibits forearm blood flow responses to bradykinin. Norepinephrine does not significantly inhibit responses to bradykinin, and Ba 2ϩ plus ouabain does not significantly inhibit acetylcholine or albuterol. This 23, 24 The simplest explanation is that bradykinin dilates this vascular bed partly but not entirely through activation of K IR . The residual vasodilator response to bradykinin in the presence of inhibitors points to the possible involvement of a direct vasodilator action of bradykinin on vascular smooth muscle or of mediator pathways distinct from NO, prostaglandins, or K ϩ ions. Activation of K IR by bradykinin could be via increased K ϩ concentration in the interstitial extracellular space in resistance arteries. The present experiments do not define the cellular origin of such increased interstitial K ϩ concentration. This could be the endothelium, as in rat hepatic artery in vitro, 9, 25 consistent with an EDHF/K ϩ -mediated mechanism of bradykinin in the forearm in vivo. This agrees with the observation that a dose of tetraethylammonium expected to give a plasma concentration of Ϸ2ϫ10 Ϫ4 mol L Ϫ1 inhibits but does not abolish responses to bradykinin in this vascular bed. 18 This concentration of tetraethylammonium could inhibit K ϩ efflux from endothelium via an action on K Ca channels, where it produces half the maximum block at Ϸ2ϫ10 Ϫ4 mol L
Ϫ1
. 7
Limitations
A constraint was our concern to limit the exposure of volunteers to Ba 2ϩ . The total infused dose of 24 mol is less than one-tenth the chronic oral reference dose calculated by the Environmental Protection Agency. Limiting the dose of Ba 2ϩ in this way meant that we were not able to explore its effects on a range of doses of bradykinin. A limitation of norepinephrine as a control is that it can inhibit K IR in vascular smooth muscle; other vasoconstrictors may influence K IR by an effect on membrane potential. Another limitation is that the present experiments do not identify the cellular distribution of the K IR channel involved in the vasodilator action of bradykinin in the forearm. This may be important because this channel is expressed not only in vascular smooth muscle but also in endothelial cells. 26 In conclusion, a dose of Ba 2ϩ that selectively inhibits K IR inhibits forearm vasodilator responses to bradykinin in healthy men, evidence that a component of this response is mediated by activation of K IR . This is consistent with bradykinin acting through K ϩ and/or another K IR -dependent EDHF in human forearm resistance vessels in vivo.
